Considerations in establishing bioequivalence of inhaled compounds

References

• Generic drugs. Ottawa (Canada): Canadian Agency for Drug Technologies in Health (CADTH); 2012 [cited 2016 Sep 12]. Available from: https://www.cadth.ca/generic-drugs
   Google Scholar
• Generic drugs: questions and answers. Silver Spring (MD): U.S. Food & Drug Administration; 2015. [cited 2016 Sep 7]. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm
   Google Scholar
• Health Canada. Guidance document: conduct and analysis of comparative bioavailability studies. Ottawa: Health Canada; 2012.
   Google Scholar
• Health Canada. Guidance document: comparative bioavailability standards: formulations used for systemic effects. Ottawa: Health Canada; 2012.
   Google Scholar
• Health Canada. Draft guidance document: data requirements for safety and effectiveness of subsequent market entry inhaled corticosteroid products for use in the treatment of asthma. Ottawa: Health Canada; 2011.
   Google Scholar
• Government of Canada. Canadian food and drug regulations c.08.002 and c.08.002.1. Ottawa: Minister of Justice, Canada; 2016.
   Google Scholar
• Evans C, Cipolla D, Chesworth T, et al. Equivalence considerations for orally inhaled products for local action-isam/ipac-rs european workshop report. J Aerosol Med Pulm Drug Deliv. 2012;25:117–139.
   PubMed Web of Science ®Google Scholar
• Government of Canada. Policy: interpretation of identical medicinal ingredient. Ottawa: Health Canada; 2003.
   Google Scholar
• Health Canada. Guidance to establish equivalence or relative potency of safety and efficacy of a second entry short-acting beta2-agonist metered dose inhaler. Ottawa: Health Canada; 1999.
   Google Scholar
• Health Canada. Health Canada scientific advisory committee on respiratory and allergy therapies - record of proceedings (item 13). Ottawa: Health Canada; 2008.
   Google Scholar
• Health Canada. Guidance for industry: pharmaceutical quality of inhalation and nasal products. Ottawa: Health Canada; 2006.
   Google Scholar
• Lee SL, Adams WP, Li BV, et al. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J. 2009;11:414–423.
   PubMed Web of Science ®Google Scholar
• Health Canada. Health Canada scientific advisory committee on respiratory and allergy therapies - record of proceedings. Ottawa: Health Canada; 2009.
   Google Scholar
• Science & research - critical path opportunities for generic drugs. Silver Spring (MD): U.S. Food and Drug Administration; 2007. [cited 2016 Sep 8]. Available from: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077250.htm
   Google Scholar
• Horhota S. Running against the wind. Can the classic paradigm for be really be extended to locally acting oindp? An analysis of the current scientific and regulatory dilemmas of inhaler evaluation. Respiratory Drug Delivery. 2012;1:283–290.
   Google Scholar
• Center for Drug Evaluation and Research. Draft guidance: bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. Rockville: Center for Drug Evaluation and Research; 2003.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on bioequivalence of fluticasone propionate; salmeterol xinafoate. Silver Spring: U.S. Food and Drug Administration; 2013.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on indacaterol maleate. Silver Spring: U.S. Food and Drug Administration; 2016.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on ipratropium bromide. Silver Spring: U.S. Food and Drug Administration; 2015.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on aclidinium bromide. Silver Spring: U.S. Food and Drug Administration; 2015.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on beclomethasone dipropionate. Silver Spring: U.S. Food and Drug Administration; 2016.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on ciclesonide. Silver Spring: U.S. Food and Drug Administration; 2016.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on formoterol fumarate; mometasone furoate. Silver Spring: U.S. Food and Drug Administration; 2016.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on budesonide; formoterol fumarate dihydrate. Silver Spring: U.S. Food and Drug Administration; 2015.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on albuterol sulfate. Silver Spring: U.S. Food and Drug Administration; 2013.
   Google Scholar
• U.S. Food and Drug Administration. Draft guidance on levalbuterol tartrate. Silver Spring: U.S. Food and Drug Administration; 2015.
   Google Scholar
• European Medicines Agency. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. London: European Medicines Agency; 2009.
   Google Scholar
• Adams WP, Ahrens RC, Chen ML, et al. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPS): workshop summary report. J Aerosol Med Pulm Drug Deliv. 2010;23:1–29.
   PubMedGoogle Scholar
• Fults K, Cyr TD, Hickey AJ. The influence of sampling chamber dimensions on aerosol particle size measurement by cascade impactor and twin impinger. J Pharm Pharmacol. 1991;43:726–728.
   PubMed Web of Science ®Google Scholar
• Dunbar C, Mitchell J. Analysis of cascade impactor mass distributions. J Aerosol Med. 2005;18:439–451.
   PubMedGoogle Scholar
• Apiou-Sbirlea G, Newman S, Fleming J, et al. Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. Ther Deliv. 2013;4:343–367.
   PubMedGoogle Scholar
• De Backer J, Van Holsbeke C, Vos W, et al. Assessment of lung deposition and analysis of the effect of fluticasone/salmeterol hydrofluoroalkane (HFA) pressurized metered dose inhaler (PMDI) in stable persistent asthma patients using functional respiratory imaging. Expert Rev Respir Med. 2016;10:927–933.
   PubMed Web of Science ®Google Scholar
• Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med. 2001;14(Suppl 1):S19–26.
   PubMedGoogle Scholar
• Scheuch G, Sommerer K, Meyer T, et al. Lung deposition studies: the challenge of interpretation. Respiratory Drug Delivery. 2004;2:513–516.
   Google Scholar
• Liu X, Jin L, Upham JW, et al. The development of models for the evaluation of pulmonary drug disposition. Expert Opin Drug Metab Toxicol. 2013;9:487–505.
   PubMed Web of Science ®Google Scholar
• Brand P, Friemel I, Meyer T, et al. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci. 2000;89:724–731.
   PubMed Web of Science ®Google Scholar
• Devadason SG, Chan HK, Haeussermann S, et al. Validation of radiolabeling of drug formulations for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25(Suppl 1):S6–9.
   PubMedGoogle Scholar
• Fleming J, Conway J, Majoral C, et al. The use of combined single photon emission computed tomography and x-ray computed tomography to assess the fate of inhaled aerosol. J Aerosol Med Pulm Drug Deliv. 2011;24:49–60.
   PubMed Web of Science ®Google Scholar
• Fleming JS, Conway JH. Three-dimensional imaging of aerosol deposition. J Aerosol Med. 2001;14:147–153.
   PubMedGoogle Scholar
• Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol. 2001;51:289–299.
   PubMed Web of Science ®Google Scholar
• Eberl S, Chan HK, Daviskas E. Spect imaging for radioaerosol deposition and clearance studies. J Aerosol Med. 2006;19:8–20.
   PubMedGoogle Scholar
• Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of respimat soft mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273–282.
   PubMedGoogle Scholar
• Pauwels R, Newman S, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997;10:2127–2138.
   PubMed Web of Science ®Google Scholar
• Newman S, Fleming J. Challenges in assessing regional distribution of inhaled drug in the human lungs. Expert Opin Drug Deliv. 2011;8:841–855.
   PubMed Web of Science ®Google Scholar
• Harrison LI, Novak CC, Needham MJ, et al. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. J Aerosol Med Pulm Drug Deliv. 2011;24:245–252.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Parkins DA, Thomas MJ, et al. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: implications for establishing bioequivalence of inhaled products. Clin Ther. 2009;31:370–385.
   PubMed Web of Science ®Google Scholar
• Talton J, Fitz-Gerald J, Singh R, et al. Nano-thin coatings for improved lung targeting of glucocorticoid dry powders: in-vitro and in-vivo characteristics. Respiratory Drug Delivery. 2000;1:67–74.
   Google Scholar
• Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54:405–414.
   PubMed Web of Science ®Google Scholar
• Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing. Am J Respir Crit Care Med. 2000;161:309–329.
   PubMed Web of Science ®Google Scholar
• Clearie KL, Williamson PA, Meldrum K, et al. Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide. Br J Clin Pharmacol. 2011;71:504–513.
   PubMed Web of Science ®Google Scholar
• Horhota ST, van Noord JA, Verkleij CB, et al. In vitro, pharmacokinetic, pharmacodynamic, and safety comparisons of single and combined administration of tiotropium and salmeterol in copd patients using different dry powder inhalers. AAPS J. 2015;17:871–880.
   PubMed Web of Science ®Google Scholar
• Kuna P, Govoni M, Lucci G, et al. Pharmacokinetics and pharmacodynamics of an extrafine fixed pmdi combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma. Br J Clin Pharmacol. 2015;80:569–580.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99.
   PubMed Web of Science ®Google Scholar
• Wise RA, Anzueto A, Calverley P, et al. The tiotropium safety and performance in respimat trial (tiospir), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res. 2013;14:40.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Geri P, Camiciottoli G, et al. Agreement between two methods for assessing bioequivalence of inhaled salbutamol. Pulm Pharmacol Ther. 2008;21:380–384.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Geri P, Mariani L, et al. Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism. Br J Clin Pharmacol. 2006;62:403–411.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kerstjens HA, Aalbers R, et al. Pharmacokinetics of tiotropium administered by respimat(r) in asthma patients: analysis of pooled data from phase II and III clinical trials. Pulm Pharmacol Ther. 2017;42:25–32.
   PubMed Web of Science ®Google Scholar
• Pirozynski M, Sosnowski TR. Inhalation devices: from basic science to practical use, innovative vs. generic products. Expert Opin Drug Deliv. 2016;13:1559–1571.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Braido F, Baiardini I, et al. Asthma and copd: interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMER). Pulm Pharmacol Ther. 2015;34:25–30.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249–254.
   PubMedGoogle Scholar
• Thomas M, Price D, Chrystyn H, et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med. 2009;9:1.
   PubMedGoogle Scholar
• Braido F, Lavorini F, Blasi F, et al. Switching treatments in COPD: implications for costs and treatment adherence. Int J Chron Obstruct Pulmon Dis. 2015;10:2601–2608.
   PubMed Web of Science ®Google Scholar
• Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75:18–25.
   PubMed Web of Science ®Google Scholar
• Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004;93:439–446.
   PubMed Web of Science ®Google Scholar
• Leiner S, Parkins D, Lastow O. Inhalation devices and patient interface: human factors. AAPS J. 2015;17:457–461.
   PubMed Web of Science ®Google Scholar